A Master Protocol to Investigate the Safety, Tolerability and Immunogenicity of Bivalent BNT162b2 RNA-Based Vaccine Candidate(s) in Healthy Infants and Children
Clinical Trial Grant
Administered By
Duke Human Vaccine Institute
Awarded By
Pfizer, Inc.
Start Date
November 14, 2022
End Date
November 13, 2023
Administered By
Duke Human Vaccine Institute
Awarded By
Pfizer, Inc.
Start Date
November 14, 2022
End Date
November 13, 2023